Related Experiment Video
Updated: Aug 23, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Fibrates in the metabolic syndrome and in diabetes
1Division of Endocrinology and Metabolism, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 2C4. george.steiner@uhn.on.ca
Abstract:
There is increasing evidence that fibrates can reduce coronary artery disease. This finding seems to be particularly the case inpatients with the metabolic syndrome or with diabetes. Their beneficial effects can be explained partly by their effects on lipoproteins,but these effects may also result from some of their nonlipid pleotropic effects. Clinical trials are still needed to determine the potential role played by such pleotropic actions.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Dipeptidyl Peptidase 4 Inhibitors
